Kyle Rizer,
Research Coordinator
Department:
MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone:
(352) 733-2426
Business Email:
kyle.rizer@neurology.ufl.edu
Publications
Academic Articles
2018
Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry.
JAMA neurology.
75(3):353-359
[DOI] 10.1001/jamaneurol.2017.4317.
[PMID] 29340590.
2017
Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.
Neurology. Clinical practice.
7(4):283-295
[DOI] 10.1212/CPJ.0000000000000371.
[PMID] 28840919.
2016
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
JAMA.
316(1):40-50
[DOI] 10.1001/jama.2016.8655.
[PMID] 27380342.
2016
The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work?
Frontiers in neuroscience.
10
[DOI] 10.3389/fnins.2016.00170.
[PMID] 27199634.
Grants
Sep 2024
ACTIVE
Pridopidine Post Trial Access Protocol in Patients with Huntington's Disease. (PTAP)
Role: Other
Funding: PRILENIA THERAPEUTICS
Jul 2024
ACTIVE
A35-009, A Phase 2b/3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)
Role: Other
Funding: AMYLYX PHARMACEUTICALS
Apr 2021
– Nov 2024
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease
Role: Other
Funding: PRILENIA THERAPEUTICS
Feb 2020
– Jun 2022
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Role: Other
Funding: ABBVIE
Jan 2020
– May 2022
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntingtons Disease
Role: Other
Funding: HUNTINGTON STUDY GROUP LTD
via NEUROCRINE BIOSCIENCES
Dec 2019
– Dec 2024
A Randomized, Double-Blind, Placebo Controlled Multiple Ascending
Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients with Parkinson's Disease
Role: Other
Funding: ABBVIE
Contact Details
Phones:
- Business:
- (352) 733-2426
Emails:
- Business:
- kyle.rizer@neurology.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 112742
GAINESVILLE FL 32611 - Business Street:
-
3009 SW WILLISTON RD
GAINESVILLE FL 32608